Gyre Therapeutics, Inc. GYRE Deferred Income Tax Expense Benefit Net
Deferred Income Tax Expense Benefit Net at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept gyre:DeferredIncomeTaxExpenseBenefitNet.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s deferred income tax expense benefit net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s deferred income tax expense benefit net?
- Gyre Therapeutics, Inc. (GYRE) reported deferred income tax expense benefit net of -$738K in Q1 2026.
- How has Gyre Therapeutics, Inc.'s deferred income tax expense benefit net changed year-over-year?
- Gyre Therapeutics, Inc.'s deferred income tax expense benefit net decreased by 286.4% year-over-year, from -$191K to -$738K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s deferred income tax expense benefit net?
- Over 3 years (2022 to 2025), Gyre Therapeutics, Inc.'s deferred income tax expense benefit net has grown at a 9.8% compound annual growth rate (CAGR), from -$838K to -$1.11M.
- What does deferred income tax expense benefit net mean?
- Represents the net change in deferred tax assets and liabilities resulting from temporary differences between financial accounting and tax reporting. This metric highlights the impact of timing differences on future tax obligations or benefits. It is a key indicator of the company's tax planning and future cash tax requirements.